BioLife Solutions Launches New High Capacity Controlled Rate Freezer Line with First Shipment to a Leading Cell Therapy Developer
Product Fills Critical Cold Chain Need to Enable High Volume Production of Allogeneic Cell Therapies
News provided by
Share this article
BOTHELL, Wash., April 15, 2021 /PRNewswire/ --
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced that it has launched a new line of high capacity controlled rate freezers (HCRF), with an initial shipment to a leading cell therapy company. The freezer will be a critical component in this customer's cold chain management of several allogeneic cell therapies in development.